Phase I Study of Weekly Nanoparticle Albumin-Bound Paclitaxel (Abraxane) + Weekly Cetuximab + Radiation Therapy (IMRT, Intensity-Modulated Radiation Therapy) in Patients With Stage III-IVB Head and Neck Squamous Cell Carcinoma (HNSCC)
Phase of Trial: Phase I
Latest Information Update: 12 Aug 2016
At a glance
- Drugs Paclitaxel (Primary) ; Cetuximab
- Indications Head and neck cancer
- Focus Adverse reactions
- 09 Aug 2016 Status changed from active, no longer recruiting to completed.
- 11 May 2015 Planned End Date changed from 1 Aug 2014 to 1 Aug 2016 as reported by ClinicalTrials.gov record.
- 11 May 2015 Planned primary completion date changed from 1 Aug 2014 to 1 Aug 2016 as reported by ClinicalTrials.gov record.